Advertisement

Topics

Companies Related to "Some Cervical Cancer Screening Strategies More Cost Effective" [Most Relevant Company Matches] RSS

15:14 EDT 16th June 2019 | BioPortfolio

Here are the most relevant search results for "Some Cervical Cancer Screening Strategies More Cost Effective" found in our extensive corporate database of over 50,000 company records.

Showing "Some Cervical Cancer Screening Strategies More Cost Effective" Companies 1–25 of 6,400+

Extremely Relevant

Mtm laboratories AG

mtm laboratories is a certified developer and manufacturer of In-vitro Diagnostics for screening and diagnosis of cervical cancer with products marketed world-wide. The privately held company is headquartered in Heidelberg, Germany, with a subsidiary in Westborough (MA), USA.mtm’s products target the largest existing screening market in oncology. The biomarker-based diagnostic assays promis...


DIAMICS, INC

Diamics mission is to work in partnership with both individual and institutional experts to develop and market cost-effective molecular-based cancer screening and diagnostic systems that will increase long-term survival rates through early detection. Cancers that can be detected earlier by screening account for at least half of all new cancer cases.1 In addition to cervical cancer, these cancers ...

CytoCore Inc.

CytoCore develops cost-effective, highly accurate screening systems for early detection of gynecological and other cancers. Designed for easy deployment at a laboratory or at the point-of-care, the CytoCore suite of sample collection technologies assists in the detection of cervical, endometrial, and other cancers. The CytoCore Solutions System is being de...


CytoCore

CytoCore, Inc. is a publicly traded biotechnology company (BB:CYCR) that is developing a proteomic-based method of screening and diagnosis for endometrial and cervical cancer. The company's major product is called the InPath™ System and is comprised of four distinct components: the e Collector™, protein-based biochemical cocktails and Slide Based Tests, the AIPS™ microscope platform, and a d...

Cervical Cancer-Free America

Cervical cancer is caused by persistent infections with high-risk types of the human papillomavirus (HPV). HPV is a very common sexually transmitted infection that 3 of 4 adults will have at some time in their lives. HPV vaccines are now available and target the two types of HPV that are responsible for 70 percent of all cervical cancers and are FDA-approved for girls and young women up to age 26....

Relevant

Enterix Inc

Enterix Inc. is a US-based biotechnology company founded in 1997 that manufactures, markets, and distributes a leading-edge product for colorectal cancer screening. The company also uses this product to provide a colorectal cancer screening service. Enterix is addressing a large and rapidly growing market where there is a demonstrated need for an easy-to-use and cost-effective screening tool – a...

Digene

A leader in molecular diagnostics, Digene develops, manufactures and markets proprietary DNA and RNA tests focused on women's cancers and infectious diseases. The company's flagship product, The Digene® HPV Test* (DNAwithPap® Test), is the only FDA–approved test for the human papillomavirus (HPV), the primary cause of cervical cancer. Rapidly emerging as a standard of practice in cervical canc...

KARD Scientific

KARD scientific is the reliable resource for all your in vivo efficacy studies in drug discovery and development. For high quality, efficiency and cost effective services in cancer, neurological, inflammation, arthritis and other disease models. We can assist you in study design and methods for screening. We optimize the schedule, time points, routes, and combination studies, while keeping cl...

VisionGate, Inc.

VisionGate, Inc. is led by Dr. Alan Nelson, physicist, bioengineer and entrepreneur who developed the world’s first and only automated screening test to detect cervical cancer, marketed today as FocalPoint by Becton Dickinson. VisionGate offers the first automated 3D cell imaging platform, the Cell-CT, which computes high-resolution 3D biosignatures f...

VisionGate Inc.

VisionGate, Inc. is led by Dr. Alan Nelson, physicist, bioengineer and entrepreneur who developed the world’s first and only automated screening test to detect cervical cancer, marketed today as FocalPoint by Becton Dickinson. VisionGate produces the first automated 3D cell imaging platform, the Cell-CT, which computes high-resolution 3D biosignatures...

Cytyc

Cytyc Corporation, based in Boxborough, Massachusetts (USA), designs, develops, manufactures, and markets sample preparation systems for medical diagnostics. Founded in 1987, Cytyc has dedicated its scientific expertise and resources to developing the ThinPrep® System to address the limitations of the 50-year-old conventional Pap smear. At the center of the ThinPrep System is the ThinPrep® Pap T...

NorDiag ASA

We at NorDiag have developed a novel, proprietary DNA-based technology for cancer testing. We believe our technology will help increase patient participation in cancer screening programmes and hasten the successful launch of new screening programmes. Key benefits to our product Genefec™ are its non-invasiveness, scalability, cost-effectiveness and its accuracy at the early stages of cancer devel...

Mediscience Technology

Mediscience Technology Corporation is engaged in the design and development of diagnostic medical devices that detect cancer using light induced native tissue fluorescence spectroscopy (the "Technology") to distinguish between malignant and normal or benign tissue. We have successfully conducted both preclinical and clinical evaluations which support the value of our proprietary technology, a br...

Gen-Probe Life Sciences Ltd

Gen-Probe Incorporated (NASDAQ: GPRO) is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) used primarily to diagnose human diseases and screen donated human blood. NATs harness the power of biotechnology to detect diseases more rapidly and/or accurately than older testing methods, and have therefore become one of the fast...

Novacyt

Novacyt, floated in 2012 on the Paris NYSE-Alternext exchange, is active in discovering, developing and marketing advanced and innovative solutions for liquid-based-cytology dedicated to cancer with a successful approval for cervical cancer screening and the opportunity to deploy its expertise in the field of molecular diagnostics. Within less than 5 years...

National Canine Cancer Foundation

The National Canine Cancer Foundation is a nationwide, contribution funded, 501 (c)(3) non-profit corporation dedicated to eliminating Cancer as a major health issue in dogs by funding grants directly to Cancer researchers who are working to save lives and find cures, better treatments and accurate, cost effective diagnostic methods in dealing with canine Cancer.

Acuamark Diagnostics, Inc.

Acuamark Diagnostics is a biotechnology company focused on developing screening tests for blood-based early detection of cancer. Acuamark Diagnostics' technology allows for highly accurate screening of blood to detect cancer markers at the early cancer stages, before the cancer becomes untreatable. Backed by a highly experienced team, it is Acuamark Diagno...

Prostate Cancer Education Council

Prostate cancer remains the second-leading cause of cancer death in American men. More than 220,000 men will be diagnosed with prostate cancer this year and it is expected that 27,000 men will die from the disease. With more annual cases of prostate cancer than that of breast cancer among women, screening is imperative to ensure the health of the men of our nation.

Exact Sciences Corp.

Exact Sciences Corp. is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the ...

Colonix Medical Limited

Colonix Medical Limited has pioneered and refined a new system for the early detection / screening of colorectal cancer and other bowel diseases such as IBD. This system can be used for both symptomatic and non symptomatic patients. Colorectal cancer is often referred to as ‘the silent killer’. If detected early, colorectal cancer treatments are effective and after treatment most sufferers ca...

MEDITE Cancer Diagnostics, Inc.

MEDITE Cancer Diagnostics Inc., is a Delaware registered company consisting of wholly-owned MEDITE GmbH a Germany-based Company, with its subsidiaries CytoGlobe GmbH (Cytology Products, Germany), MEDITE GmbH (Distributor, Austria), MEDITE Inc. (Distributor, Americas) and MEDITE sp. z o.o. (R&D Poland). MEDITE specializes in the development, manufacture and...

StopColonCancerNow.com

StopColonCancerNow.com is a community of more than 700 physicians who have joined forces to promote education and awareness about colon cancer screening and prevention. AmSurg, provider of approximately one in every 10 colonoscopies in the United States, launched the campaign in 2009 as part of its commitment to provide the highest level of care and inform...

IncellDx, Inc.

IncellDx, Inc. is a molecular diagnostics company dedicated to revolutionizing healthcare one cell at a time. By combining molecular diagnostics with high throughput cellular analysis, we focus on critical life threatening diseases such as HIV/AIDS, HPV/Cervical Cancer, Hepatitis, organ transplant infections, breast cancer and ovarian cancer.

Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines ...

Providence Medical Technology, Inc.

Providence Medical Technology is a privately held medical device company developing minimally invasive solutions addressing the $1 billion worldwide cervical fusion market. The company is commercializing the DTRAX platform of cervical devices, which are used to provide indirect decompression and fusion in patients suffering from cervical radiculopat...


More From BioPortfolio on "Some Cervical Cancer Screening Strategies More Cost Effective"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks